Bandaram Pharma

Why is Bandaram Pharma Packtech Ltd falling/rising?

As of 03-Aug, Bandaram Pharma Packtech Ltd's stock is at Rs. 20.31, down 1.41%, and has reached a new 52-week low. The stock has significantly underperformed the market, with a 1-week decline of 7.68% and a yearly return of -45.09%, reflecting weak fundamentals and concerns about its financial health.

As of 03-Aug, Bandaram Pharma Packtech Ltd's stock price is falling, currently at Rs. 20.31, which reflects a decrease of Rs. 0.29 or 1.41%. The stock has been on a downward trend, having lost 6.56% over the past two days and is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, the stock has reached a new 52-week low of Rs. 19.8 today.<BR><BR>In terms of performance relative to the market, Bandaram Pharma has underperformed significantly, with a 1-week decline of 7.68% compared to a 2.35% gain in the Sensex. Over the past year, the stock has generated a return of -45.09%, while the broader market has only declined by 2.43%. This underperformance is compounded by weak long-term fundamentals, including a low Return on Capital Employed (ROCE) of 5.33% and a high Debt to EBITDA ratio of 8.23 times, indicating challenges in servicing debt.<BR><BR>Despite some positive results in net sales growth and profit after tax in the recent quarter, the overall financial health of the company appears weak, with profits having fallen by 66% over the past year. The combination of these factors contributes to the stock's decline, as investors may be concerned about the company's ability to recover and generate sustainable returns.

Which are the latest news on Bandaram Pharma?

How big is Bandaram Pharma?

As of 10th June, Bandaram Pharma Packtech Ltd has a market capitalization of 51.00 Cr, with recent net sales of 62.92 Cr and a net profit of 0.33 Cr. Shareholder's funds are 12.65 Cr, and total assets amount to 38.92 Cr.

As of 10th June, Bandaram Pharma Packtech Ltd has a market capitalization of 51.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Bandaram Pharma reported Net Sales of 62.92 Cr and a Net Profit of 0.33 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 12.65 Cr and Total Assets totaling 38.92 Cr.

Who are in the management team of Bandaram Pharma?

The management team of Bandaram Pharma includes Kishan Prasad Palayu (Chairman), Mahesh Kumar Vellaboyina (Non Executive Director), Sangam Venkateshwar Rao (Non Executive Director), Namrata Chadha (Non Executive Independent Director), and Shivarama Babu Velchuri (Executive Director).

The management team of Bandaram Pharma includes the following individuals:<BR><BR>1. **Kishan Prasad Palayu** - Chairman<BR>2. **Mahesh Kumar Vellaboyina** - Non Executive Director<BR>3. **Sangam Venkateshwar Rao** - Non Executive Director<BR>4. **Namrata Chadha** - Non Executive Independent Director<BR>5. **Shivarama Babu Velchuri** - Executive Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

Who are the peers of the Bandaram Pharma?

Bandaram Pharma's peers include Choksi Laborator, Royal Sense, Shree Pacetronix, Amkay Products, KMS Medisurgi, N G Industries, Samsrita Labs, Deccan Healthcar, and GKB Ophthalmics. In terms of management risk, growth, and capital structure, Royal Sense and Shree Pacetronix perform best, while Bandaram Pharma shows below-average management risk and growth with a 1-year return of -25.32%.

Peers: The peers of Bandaram Pharma are Choksi Laborator, Royal Sense, Shree Pacetronix, Amkay Products, KMS Medisurgi, N G Industries, Samsrita Labs, Deccan Healthcar, and GKB Ophthalmics.<BR><BR>Quality Snapshot: Excellent management risk is observed at Royal Sense, Shree Pacetronix, Amkay Products, N G Industries, while Average management risk is found at KMS Medisurgi. Below Average management risk is noted at Choksi Laborator, Bandaram Pharma, Deccan Healthcar, and GKB Ophthalmics, and the rest have varying ratings. Growth is Excellent at Royal Sense, Good at Choksi Laborator, Shree Pacetronix, Bandaram Pharma, and Deccan Healthcar, while Below Average growth is seen at Amkay Products, KMS Medisurgi, N G Industries, and the rest. Capital Structure is Good at Royal Sense, Shree Pacetronix, Amkay Products, KMS Medisurgi, N G Industries, while Below Average is noted at Choksi Laborator, Bandaram Pharma, Deccan Healthcar, and GKB Ophthalmics.<BR><BR>Return Snapshot: Shree Pacetronix has the highest 1-year return at 66.87%, while Royal Sense has the lowest at -57.28%. Bandaram Pharma's 1-year return of -25.32% is better than Royal Sense but worse than Shree Pacetronix. Additionally, Choksi Laborator, Royal Sense, Amkay Products, N G Industries, Deccan Healthcar, and GKB Ophthalmics all have negative six-month returns.

What does Bandaram Pharma do?

Bandaram Pharma Packtech Ltd processes and supplies recycled paper within the Healthcare Services industry, having transitioned from manufacturing latex gloves since its incorporation in 1991. As of March 2026, it reported net sales of 26 Cr and a market cap of INR 51 Cr.

Overview:<BR>Bandaram Pharma Packtech Ltd is engaged in the processing and supply of recycled paper and operates within the Healthcare Services industry, categorized as a micro-cap company.<BR><BR>History:<BR>The company was incorporated on December 2, 1991, originally to manufacture latex gloves. It later ventured into the paper industry and has been operating in this line since 2022. The latest quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 26 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 51 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 153.00<BR>- Industry P/E: 92<BR>- Dividend Yield: 0.05%<BR>- Debt-Equity: 0.87<BR>- Return on Equity: 1.23%<BR>- Price to Book: 1.88<BR><BR>Contact Details:<BR>Address: 601 5th Floor Oxford Towers, Old Airport Road Kodihalli Bangalore Karnataka : 560008<BR>Email: contact@shivamedicare.com<BR>Website: http://www.bandaram.com

Should I buy, sell or hold Bandaram Pharma Packtech Ltd?

Are Bandaram Pharma Packtech Ltd latest results good or bad?

Bandaram Pharma Packtech Ltd's latest results show strong revenue growth of 76.95% quarter-on-quarter and 209.31% year-on-year, but profitability has declined significantly, with net profit down 52.63% from the previous quarter. Overall, the financial metrics indicate more concerns than positives, suggesting caution for investors.

Bandaram Pharma Packtech Ltd's latest results present a mixed picture, leaning towards negative overall. In Q4 FY26, the company reported a significant revenue increase of 76.95% quarter-on-quarter and an impressive 209.31% year-on-year growth, reaching ₹26.26 crores. However, this strong top-line performance was overshadowed by a substantial decline in profitability. <BR><BR>The net profit fell to ₹0.09 crores, reflecting a 52.63% decrease from the previous quarter and a 40% drop year-on-year. Operating margins also deteriorated sharply, dropping to 3.12% from 6.81% in the prior quarter, indicating severe cost pressures and challenges in maintaining profitability despite higher sales.<BR><BR>The company's financial health is further questioned by low return ratios, with a return on equity (ROE) of just 5.15% and a return on capital employed (ROCE) of 5.75%. Additionally, the high debt levels and negative operating cash flow raise concerns about its financial stability.<BR><BR>Overall, while Bandaram Pharma has demonstrated strong revenue growth, the significant decline in profitability and operational challenges suggest that the latest results are more concerning than positive. Investors should be cautious given the current financial metrics and market positioning.

When is the next results date for Bandaram Pharma Packtech Ltd?

The next results date for Bandaram Pharma Packtech Ltd is 30 May 2026.

The next results date for Bandaram Pharma Packtech Ltd is scheduled for 30 May 2026.

How has been the historical performance of Bandaram Pharma?

Bandaram Pharma has shown steady growth in net sales and profit over the past three years, with net sales increasing from 18.73 Cr in Mar'23 to 36.96 Cr in Mar'25, and profit after tax rising from 0.26 Cr to 0.99 Cr. Total assets and liabilities also grew significantly during this period, while cash flow from operating activities remained negative but stable.

Answer:<BR>The historical performance of Bandaram Pharma shows a steady growth in net sales and profit over the past three years.<BR><BR>Breakdown:<BR>Bandaram Pharma's net sales increased from 18.73 Cr in Mar'23 to 34.08 Cr in Mar'24, and further to 36.96 Cr in Mar'25, indicating a consistent upward trend. Total operating income mirrored this growth, reaching 36.96 Cr in Mar'25. The total expenditure also rose, from 17.57 Cr in Mar'23 to 34.14 Cr in Mar'25, primarily driven by raw material costs and employee expenses. Operating profit (PBDIT) improved from 1.35 Cr in Mar'23 to 2.91 Cr in Mar'25, while profit before tax rose from 0.33 Cr to 1.32 Cr in the same period. Profit after tax followed suit, increasing from 0.26 Cr in Mar'23 to 0.99 Cr in Mar'25. The company's total assets grew significantly from 20.17 Cr in Mar'23 to 38.92 Cr in Mar'25, alongside total liabilities which increased from 20.17 Cr to 38.92 Cr. Cash flow from operating activities remained negative but stable at -4.00 Cr in both Mar'24 and Mar'25, while cash flow from financing activities showed a positive trend, reaching 5.00 Cr in Mar'25. Overall, Bandaram Pharma has demonstrated solid growth in sales and profitability, alongside an increase in both assets and liabilities.

Is Bandaram Pharma overvalued or undervalued?

As of November 28, 2025, Bandaram Pharma is considered overvalued with a PE ratio of 216.00 and a valuation grade of attractive, despite strong short-term returns, due to negative year-to-date and one-year performance.

As of 28 November 2025, Bandaram Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in perception regarding its worth. The company is currently considered overvalued, with a PE ratio of 216.00, a Price to Book Value of 3.71, and an EV to EBITDA of 30.28. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Bandaram Pharma's PE ratio is significantly higher than Lenskart Solutions at 241.34 and Poly Medicure at 54.51, both of which are also considered expensive. The PEG ratio of 51.30 further emphasizes the overvaluation, especially when compared to the industry standards. While Bandaram Pharma has shown strong short-term returns, outperforming the Sensex in the past week and month, its year-to-date and one-year returns are negative, which adds to the concern regarding its current valuation.

Who are the top shareholders of the Bandaram Pharma?

The top shareholder of Bandaram Pharma is B. Deepak Reddy, holding 39.38% of the shares, with no pledged promoter holdings. The highest public shareholder is Sanivarapu Jhansi at 6.54%, while individual investors collectively own 23.74%.

The top shareholders of Bandaram Pharma include the promoters, with B. Deepak Reddy holding the largest stake at 39.38%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Sanivarapu Jhansi, who owns 6.54% of the shares. Additionally, individual investors collectively hold 23.74% of the company's shares.

What is the technical trend for Bandaram Pharma?

As of May 5, 2025, Bandaram Pharma's technical trend has shifted to a bearish stance with moderate strength, indicated by bearish signals from the MACD, Bollinger Bands, and moving averages, alongside a bearish monthly RSI.

As of 5 May 2025, the technical trend for Bandaram Pharma has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this assessment include the weekly MACD and Bollinger Bands both signaling bearish trends, alongside a bearish reading from the daily moving averages. The monthly RSI also indicates bearish momentum, while the KST and Dow Theory show mildly bearish conditions on a monthly basis. Overall, the combination of these indicators suggests a prevailing bearish sentiment in the market for Bandaram Pharma.

Has Bandaram Pharma declared dividend?

Bandaram Pharma Packtech Ltd has declared a 1% dividend, amounting to 0.1 per share, with an ex-date of September 20, 2024. Total returns have varied significantly across periods, with a 5-year total return of 166.14%, despite some shorter periods showing negative returns.

Bandaram Pharma Packtech Ltd has declared a 1% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1%<BR>- Amount per share: 0.1<BR>- Ex-date: 20 Sep 2024<BR><BR>Dividend Yield: 0.05%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -15.87%, with a dividend return of 0%, resulting in a total return of -15.87%.<BR><BR>Over the 1-year period, the price return was 7.69%, the dividend return was 0.30%, leading to a total return of 7.99%.<BR><BR>For the 2-year period, the price return was -49.75%, with no dividend return, resulting in a total return of -49.75%.<BR><BR>In the 3-year period, the price return was 0%, and there was no dividend return, leading to a total return of 0.0%.<BR><BR>During the 4-year period, the price return was 165.45%, with no dividend return, resulting in a total return of 165.45%.<BR><BR>For the 5-year period, the price return was 165.45%, with a dividend return of 0.69%, leading to a total return of 166.14%.<BR><BR>Overall, while Bandaram Pharma has declared a dividend, the total returns over various periods show significant variability, with some periods reflecting substantial gains, particularly over the longer term, despite certain periods showing negative returns.